WG
FOLD

Winton Group’s Amicus Therapeutics FOLD Stock Holding History

Winton Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,256
Closed -$184K – 925
2018
Q3 		$184K Buy
15,256
+419
+3% +$5.86K ﹤0.01% 982
2018
Q2 		$232K Sell
14,837
-10,612
-42% -$160K 0.01% 924
2018
Q1 		$383K Buy
+25,449
New +$387K 0.01% 885

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Winton Group's FOLD Position: Q4 2018 in Review

Winton Group sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 15,256 shares — an estimated $184K sold.

Winton Group first reported a position in FOLD in Q1 2018 and held it in 3 quarters. The position peaked at $383K in Q1 2018. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Winton Group reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Winton Group sold 15,256 Amicus Therapeutics shares in Q4 2018, an estimated $184K.
  • Winton Group first reported a position in Amicus Therapeutics in Q1 2018 and held it in 3 quarters.
  • Winton Group's Amicus Therapeutics position peaked at $383K in Q1 2018.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Winton Group's 13F filing for Q4 2018, filed 5 Feb 2019.